Jasper Therapeutics Inc Stock Price, News & Analysis

Jasper Therapeutics, Inc. (NASDAQ: JSPR) has initiated a Phase 1/2 clinical trial at Stanford University to evaluate JSP191 as a conditioning agent for patients with Fanconi Anemia requiring bone marrow transplants. This research aims to improve donor stem cell engraftment while reducing toxicity. The trial is led by Dr. Rajni Agarwal and focuses on assessing treatment-emergent adverse events among participants. JSP191, previously tested in over 100 patients, is designed to facilitate safer allogeneic transplants. Jasper also plans further clinical trials expanding JSP191's applications.

Jasper Therapeutics reported a successful FDA meeting to initiate registrational studies for JSP191, focusing on patients with MDS and AML, expected by Q1-2023. Clinical data showed JSP191 was well tolerated, with 20 out of 24 patients free from disease progression. R&D expenses rose to $8.2 million due to increased trial costs. Cash reserves stood at $70.4 million, sufficient for operations through early 2023. The company aims to advance targeted therapies for hematopoietic stem cell transplants.

Jasper Therapeutics announced plans to initiate registrational studies for JSP191, a conditioning agent for older patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) undergoing transplants. After positive feedback from the FDA, the study protocol is being finalized with no additional studies required before initiation. Recent data showed JSP191 was well tolerated in 24 older patients with successful engraftment and minimal adverse events. The company aims to launch the study early next year, enhancing treatment outcomes for this vulnerable population.

Jasper Therapeutics (NASDAQ: JSPR) announced promising results from its Phase 1b trial of JSP191, an anti-CD117 monoclonal antibody, for treating older patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). The study showed no treatment-related severe adverse events in 24 patients, all of whom achieved neutrophil recovery. Additionally, 20 patients were free from disease progression at the last follow-up. The company plans to initiate a registration study for JSP191 as a conditioning agent in upcoming hematopoietic stem cell transplants, aiming to improve treatment safety for older patients.

Jasper Therapeutics (NASDAQ: JSPR) will host a KOL webinar on April 28, 2022, at 1:00 p.m. ET, focusing on advancements in hematopoietic stem cell therapies. Key opinion leaders, Dr. Lori Muffly and Dr. David Sallman, will discuss the current challenges in stem cell transplant conditioning and myelodysplastic syndromes (MDS) treatment. The presentation will highlight JSP191, a targeted monoclonal antibody in clinical development, showcasing its potential in addressing transplant conditioning limitations for lower-risk MDS patients. A live Q&A session will follow the presentations.

Jasper Therapeutics (NASDAQ: JSPR) announced that updated data on JSP191, a monoclonal antibody, has been accepted for presentation at the 2022 Clinical Immunology Society Annual Meeting in Charlotte, NC, from March 31 to April 3. The study shows JSP191's potential to improve donor cell engraftment and immune reconstitution in severe combined immunodeficiency (SCID) patients who have failed previous transplants. CEO Ronald Martell emphasized the importance of this data for the SCID community, highlighting their commitment to delivering targeted therapies for these patients.

Jasper Therapeutics (Nasdaq: JSPR) announced on March 21, 2022, the granting of an option for 1,704,328 shares of common stock to new CEO Ronald Martell. This option, part of the 2022 Inducement Equity Incentive Plan, carries an exercise price of $3.54 per share and will vest over four years. Jasper focuses on hematopoietic cell transplantation therapies, notably advancing its anti-CD117 monoclonal antibody, JSP191, aimed at improving transplantation safety and effectiveness. The company remains committed to developing innovative therapies for life-threatening conditions.

Jasper Therapeutics (NASDAQ: JSPR) announced management changes effective March 21, 2022, including Jeet Mahal as Chief Operating Officer and Wendy Pang, M.D., Ph.D., as Senior Vice President of Research and Translational Medicine. A search for a Chief Medical Officer is underway. These moves aim to streamline operations and enhance clinical development for JSP191, a monoclonal antibody in clinical trials for AML/MDS. CEO Ronald Martell highlighted the need for a stronger organizational structure to support upcoming pivotal trials and pipeline execution.

Jasper Therapeutics (NASDAQ: JSPR) reported its fiscal year 2021 results, highlighting significant advancements in its JSP191 therapy for hematopoietic stem cell transplants. In a Phase 1b study, JSP191 demonstrated a safety record with 100% engraftment and MRD clearance in patients. The company plans to initiate pivotal studies for MDS/AML and a second-line therapeutic study in 2022. Financially, it ended 2021 with $84.7 million in cash, sufficient to fund operations into early 2023. R&D expenses increased to $25.4 million, while net loss decreased slightly to $30.6 million.